Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) have received an average rating of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $20.50.

Several analysts have recently commented on ADPT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. BTIG Research reissued a “buy” rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a research note on Wednesday, June 17th. JPMorgan Chase & Co. decreased their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Wall Street Zen cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, TD Cowen increased their price target on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th.

Insider Transactions at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Francis Lo sold 39,741 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $17.49, for a total value of $695,070.09. Following the transaction, the insider owned 250,934 shares in the company, valued at approximately $4,388,835.66. This represents a 13.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Julie Rubinstein sold 30,941 shares of the stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $14.83, for a total transaction of $458,855.03. Following the completion of the sale, the chief operating officer owned 434,188 shares of the company’s stock, valued at approximately $6,439,008.04. The trade was a 6.65% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 698,316 shares of company stock worth $11,655,488. 5.70% of the stock is owned by company insiders.

Institutional Trading of Adaptive Biotechnologies

A number of institutional investors have recently bought and sold shares of the company. 1492 Capital Management LLC bought a new position in Adaptive Biotechnologies during the fourth quarter valued at about $1,484,000. Jupiter Asset Management Ltd. boosted its stake in shares of Adaptive Biotechnologies by 33.8% during the 4th quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock worth $5,892,000 after acquiring an additional 91,683 shares in the last quarter. Rhenman & Partners Asset Management AB boosted its stake in shares of Adaptive Biotechnologies by 22.2% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company’s stock worth $9,825,000 after acquiring an additional 110,000 shares in the last quarter. UBS Group AG increased its holdings in shares of Adaptive Biotechnologies by 101.6% during the 4th quarter. UBS Group AG now owns 511,927 shares of the company’s stock valued at $8,314,000 after acquiring an additional 257,947 shares during the last quarter. Finally, Jennison Associates LLC raised its stake in shares of Adaptive Biotechnologies by 103.9% in the 4th quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock valued at $43,437,000 after acquiring an additional 1,363,181 shares in the last quarter. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Stock Performance

Shares of NASDAQ:ADPT opened at $21.19 on Friday. The company has a market cap of $3.39 billion, a PE ratio of -64.21 and a beta of 2.07. Adaptive Biotechnologies has a 52 week low of $9.96 and a 52 week high of $22.80. The firm has a 50 day simple moving average of $16.09 and a 200 day simple moving average of $15.86.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The firm had revenue of $70.87 million for the quarter, compared to analysts’ expectations of $61.03 million. During the same period in the previous year, the company posted ($0.20) EPS. The company’s quarterly revenue was up 35.1% compared to the same quarter last year. On average, equities analysts predict that Adaptive Biotechnologies will post -0.47 earnings per share for the current year.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.